| Name | Title | Contact Details |
|---|---|---|
Frederic-Andre Vennat |
Executive Director, Program Management Office Lead, Human Health | Profile |
Jacob Langbein |
Director, Global Marketing | Profile |
Greg Elwood |
Associate Director, US Payer Marketing | Profile |
Ali Guerrieri |
Associate Director Consumer Marketing | Profile |
Anoop Kumar |
Director Financial Systems, Life Science | Profile |
ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize Cortrophin gel and Cortrophin-Zinc.
Our first-of-its-kind software system lets clinical research investigators create e-source templates and use a mobile tablet to capture source data. Research sites can save time, improve accuracy and reduce protocol deviations through our autofill and data validation techniques. Our system also has patient scheduling, recruiting and financial management for a holistic, all-in-one enterprise solution.
Gerigene Medical Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.
Mission Pharmacal is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.